HeartSciences Inc. (HSCS)
NASDAQ: HSCS · Real-Time Price · USD
3.580
-0.010 (-0.28%)
Jun 6, 2025, 4:00 PM - Market closed
HeartSciences Revenue
In the fiscal year ending April 30, 2024, HeartSciences had annual revenue of $18.60K with 261.17% growth.
Revenue (ttm)
$18.60K
Revenue Growth
+261.17%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
15
Market Cap
3.87M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Apr 30, 2024 | 18.60K | 13.45K | 261.17% |
Apr 30, 2023 | 5.15K | -9.22K | -64.17% |
Apr 30, 2022 | 14.37K | -11.23K | -43.86% |
Apr 30, 2021 | 25.60K | -38.58K | -60.11% |
Apr 30, 2020 | 64.18K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
HSCS News
- 4 days ago - HeartSciences Receives FDA Breakthrough Device Designation for MyoVista Insights AI-ECG Algorithm for Detecting Aortic Stenosis - GlobeNewsWire
- 5 days ago - Foundational US Patent Granted for ECG Assessment of Heart Function, Further Expands HeartSciences' Patent Portfolio and IP Value - GlobeNewsWire
- 10 days ago - HeartSciences Signs First MyoVista Insights™ Platform Customer, Marking Major Commercial Milestone - GlobeNewsWire
- 19 days ago - HeartSciences' CEO Andrew Simpson to Present at Emerging Growth Conference 82 on Wednesday, May 21, 2025 - GlobeNewsWire
- 4 weeks ago - HeartSciences to Host Investor Webinar and Q&A on Wednesday May 14, 2025 - Featuring CEO Andrew Simpson - GlobeNewsWire
- 4 weeks ago - HeartSciences Adds Prominent Key Advisors to its Scientific Advisory Board - GlobeNewsWire
- 5 weeks ago - HeartSciences Announces Launch of MyoVista Insights™ Platform and Related Early Adopter Program - GlobeNewsWire
- 3 months ago - HeartSciences Provides Business Update and Reports Third Quarter Fiscal 2025 Financial Results - GlobeNewsWire